中国医师协会介入医师分会临床诊疗指南专委会

通信作者：滕皋军，东南大学附属中大医院介入与血管外科，南京 210009，Email：该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。

【摘要】 经动脉介入治疗（TAI）应用于肝细胞癌（HCC），主要包括经动脉化疗栓塞（TACE）、经动脉栓塞（TAE）、肝动脉灌注化疗（HAIC）和选择性内放射治疗（SIRT）。TACE是治疗不可切除HCC的首选方法，中国医师协会介入医师分会（CCI）分别于2018、2021和2023年制订并更新了《中国肝细胞癌经动脉化疗栓塞（TACE）治疗临床实践指南》，为规范我国 TACE 临床实践发挥了重要作用。近年来，HAIC、SIRT在国内的应用日趋广泛并不断规范。随着TAI技术的进步、治疗理念的更新以及近年来高级别循证医学证据的出现，CCI在既往指南内容基础上，整合TACE、HAIC、SIRT内容并更新颁布《中国肝细胞癌经动脉介入治疗临床实践指南（2026版）》。本指南以最新循证医学证据为基础，结合我国临床实践，涵盖了TAI应用于HCC治疗的新进展，从临床诊断标准与分期、患者适应证与禁忌证、操作流程及要求、围手术期处理、常见并发症及处理、随访及疗效评价、联合治疗、质量控制及热点和展望等方面阐述，旨在进一步规范TAI在HCC治疗中的应用。

【关键词】 癌，肝细胞； 介入放射学，治疗性； 实践指南； 经动脉介入治疗

实践指南注册：国际实践指南注册与透明化平台（PREPARE‑2025CN046）

Chinese clinical practice guidelines for transarterial interventions of hepatocellular carcinoma (2026 edition)

Clinical Guidelines Committee of Chinese College of Interventionalists

Corresponding author: Teng Gaojun, Center of Interventional Radiology & Vascular Surgery, Department of Radiology, Zhongda Hospital, Southeast University, Nanjing 210009, China, Email: 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。

【Abstract】 Transarterial interventions (TAI) for hepatocellular carcinoma (HCC) include transarterial chemoembolization (TACE), transarterial embolization (TAE), hepatic arterial infusion chemotherapy (HAIC), and selective internal radiation therapy (SIRT). TACE remains the first‑line treatment for unresectable HCC. Chinese College of Interventionalists (CCI) previously issued and updated the Chinese Clinical Practice Guidelines of TACE for HCC in 2018, 2021, and 2023, which have played a pivotal role in standardizing TACE procedures in China. In recent years, the application of HAIC and SIRT has become increasingly widespread and standardized in China. With the continuous advancement of TAI techniques, the evolution of therapeutic concepts, and the emergence of high‑level evidence, CCI has comprehensively revised and expanded its previous guidelines. The updated Chinese clinical practice guidelines for transarterial interventions of hepatocellular carcinoma (2026 edition) now formally incorporates TACE, HAIC, and SIRT as standard treatment modalities. With the aims to further standardize the use of TAI in the management of HCC, this guideline is developed based on the most current evidence‑based medical research, integrates China‑specific clinical practices, and incorporates the latest advancements in TAI for HCC. It elaborates on clinical diagnostic criteria and staging, patient indications and contraindications, operational procedures and requirements, perioperative management, common complications management, follow‑up and efficacy evaluation, combination therapy, quality control, as well as hot topics and prospects.

【Key words】 Carcinoma, hepatocellular; Interventional radiology, therapeutic; Practice guideline; Transarterial interventions

Practice guideline registration: Practice Guideline Registration for Transparency (PREPARE‑2025CN046)